VIDEO: COMMANDS study could have implications for myelofibrosis treatment
In this video, Ruben Mesa, MD, discussed the results of the phase 3 COMMANDS study, pertaining to low-risk myelodysplastic syndrome, presented at ASCO Annual Meeting.
Mesa, executive director of Atrium Health Wake Forest Baptist Comprehensive Cancer Center, said the study presented data suggesting that luspatercept (Reblozyl; Celgene, Bristol Myers Squibb) could improve quality of life in place of or addition to erythropoiesis-stimulating agent (ESA) therapy — and could have implications for myelofibrosis.
“In many ways low-risk MDS with cytopenia certainly overlaps with some of the pathophysiology of myelofibrosis,” Mesa said. “Bone marrow making less cells are clearly implications for patients.”
Reference:
Garcia-Manero G, et al. Abstract 7003. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Collapse
Read more about